PMV Pharmaceuticals (PMVP) Projected to Post Earnings on Monday

PMV Pharmaceuticals (NASDAQ:PMVP) is expected to be issuing its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect PMV Pharmaceuticals to post earnings of ($0.40) per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 6, 2026 at 9:30 AM ET.

PMV Pharmaceuticals Stock Down 1.9%

Shares of PMV Pharmaceuticals stock opened at $1.04 on Monday. The company has a market capitalization of $55.34 million, a price-to-earnings ratio of -0.65 and a beta of 1.40. The stock’s 50-day simple moving average is $1.15 and its 200-day simple moving average is $1.30. PMV Pharmaceuticals has a 52 week low of $0.81 and a 52 week high of $1.84.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of PMV Pharmaceuticals in a research report on Monday, December 29th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $5.00.

Hedge Funds Weigh In On PMV Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of PMVP. Shay Capital LLC purchased a new position in PMV Pharmaceuticals during the 2nd quarter worth $26,000. Squarepoint Ops LLC boosted its holdings in PMV Pharmaceuticals by 101.8% in the fourth quarter. Squarepoint Ops LLC now owns 26,502 shares of the company’s stock worth $33,000 after acquiring an additional 13,367 shares in the last quarter. Public Employees Retirement System of Ohio boosted its holdings in PMV Pharmaceuticals by 349.7% in the fourth quarter. Public Employees Retirement System of Ohio now owns 27,434 shares of the company’s stock worth $34,000 after acquiring an additional 21,334 shares in the last quarter. Algert Global LLC purchased a new stake in shares of PMV Pharmaceuticals during the third quarter worth about $87,000. Finally, Jacobs Levy Equity Management Inc. acquired a new position in shares of PMV Pharmaceuticals during the third quarter valued at about $96,000. 90.20% of the stock is owned by hedge funds and other institutional investors.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc and changed its name to PMV Pharmaceuticals, Inc in July 2013. PMV Pharmaceuticals, Inc was incorporated in 2013 and is based in Princeton, New Jersey.